These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24202965)

  • 1. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
    Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
    Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
    Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
    FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL; Allison JM; Shimizu Y; ElShamy WM
    Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
    Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
    Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax.
    Kim CW; Lu JN; Go SI; Jung JH; Yi SM; Jeong JH; Hah YS; Han MS; Park JW; Lee WS; Min YJ
    Int J Oncol; 2013 Nov; 43(5):1495-502. PubMed ID: 23970333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of FAM3B Promotes Cisplatin Resistance in Gastric Cancer by Inducing Epithelial-Mesenchymal Transition.
    Song C; Duan C
    Med Sci Monit; 2020 May; 26():e921002. PubMed ID: 32442162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients.
    Nakamura M; Tsuji N; Asanuma K; Kobayashi D; Yagihashi A; Hirata K; Torigoe T; Sato N; Watanabe N
    Cancer Sci; 2004 Jan; 95(1):44-51. PubMed ID: 14720326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway.
    Zhou D; Liu W; Liang S; Sun B; Liu A; Cui Z; Han X; Yuan L
    Cancer Med; 2018 Apr; 7(4):1369-1383. PubMed ID: 29522284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
    Zhao Z; Li C; Xi H; Gao Y; Xu D
    Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
    Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
    Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
    Sun T; Zhang J; Deng B; Fan X; Long T; Jin H; Tao S; Kang P; Tan Q
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1348-1359. PubMed ID: 33167006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
    Wang XJ; Feng CW; Li M
    Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
    Su J; Zhang F; Li X; Liu Z
    Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.